Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Phase 2

• Conditions: Cancer; Lung Cancer Metastatic; MET Gene Mutation
• Interventions: Drug: Capmatinib

• Registration Number: NCT03693339
• Lead Sponsor: Asan Medical Center

Brief Summary

This study is a phase II, single-arm, open label study under an umbrella trial for NSCLC. This clinical study is targeted for the patients who harbor exon 14 skipping mutation of MET and all patients will be treated with Capmatinib. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.

Detailed Description

Not available

Study Timeline

• Status Verified: 2018-10
• Study First Submitted: 2018-10-01
• Study First Submitted QC: 2018-10-01
• Last Update Submitted: 2018-10-01
• Study First Posted: 2018-10-03
• Last Update Posted: 2018-10-03
• Study Start: 2018-10-30
• Primary Completion: 2020-06-30
• Study Completion: 2022-06-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

• Subjects with histologically or cytologically confirmed, unresectable stage IIIB/IV NSCLC that carries MET exon 14 skipping alteration by molecular testing, as per NGS and RT PCR.
• ECOG performance status of 0 to 2
• Male or female; ≥ 18
• Subjects with measurable lesion (using RECIST 1.1 criteria)
• Subjects must have archival tissue sample available, collected either at the time of diagnosis of NSCLC or any time since
• Patients who have progressed during or after 1st line or 2nd line therapy prior to the first dose of capmatinib. For patient who have received prior platinum containing adjuvant, neoadjuvant, or definitive chemoradiation for locally advanced disease, those treatments are regarded as 1st line if the progression has occurred < 12 months from last therapy.

Read More

Exclusion Criteria

• Any major operation or irradiation within 4 weeks of baseline disease assessment
• Any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug
• Subjects with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms
• Patients who have received more than 2 lines of prior systemic therapy, which include chemo, immune and targeted therapy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Capmatinib	Capmatinib	Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)

Primary Outcome Measures

Name	Time	Method
Objective response rate	At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months]	ORR is a proportion of patients with a best overall response defined as complete response or partial response by RECIST1.1

Secondary Outcome Measures

Name	Time	Method
Progression-free survival	At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months	PFS is defined as time from the first dose of investigational products (IPs) to progression or death due to any cause.; OS is defined as time from the first dose of IPs to death due to any cause.
Duration of response	At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months	DOR is calculated as the time from the date of the first document of complete remission (CR) or partial remission (PR) to the first documented preogressive disease (PD) or death due to any cause for patients with PR or CR.
Overall survival	At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months

Trial Locations

Locations (1)

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of